Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
The first of four planned modules at the new plant is expected to come online by summer 2026
Gefion, powered entirely by renewable energy, boasts more than 1,500 NVIDIA GPUs
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
Expanding US operations to address the increased demand for API development and manufacturing
Strengthening capabilities in Peptide Therapeutics and CDMO services
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Site Enhances New Modality CRDMO Platform Capacity for Customers
Subscribe To Our Newsletter & Stay Updated
